Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast
Patients with microinvasive carcinoma often have favorable prognosis, but it remains unclear whether this special type of breast cancer represents a distinct morphological entity with its own biological features and clinical behavior distinct from those of ductal carcinoma in situ (DCIS). The study is a retrospective analysis of a large patient cohort from a single institution. One hundred and thirty one microinvasive carcinoma and 451 DCIS cases were collected. ER, PR, HER2, and Ki67 were examined by immunohistochemistry in pathological sections. We assessed the clinicopathologic characteristics, molecular features, and survival status of microinvasive carcinoma and compared to those of DCIS. Microinvasive carcinoma differed from DCIS with respect to tumor size, lymph node status, and initial presentation (P < 0.05). There was a significant difference in nuclear grade among microinvasive carcinoma of different molecular subtype (P < 0.05). The clinicalpathologic features and outcomes of patients with microinvasive carcinoma were similar to those with DCIS. The 5-year OS rate for microinvasive carcinoma and DCIS patients was 99.0 and 99.2 %, respectively. A combination of pathologic, clinical, and molecular factors may ultimately reveal more powerful and robust measures for disease classification than any one modality alone. Microinvasive carcinoma does not significantly predict for worse DFS or OS in comparison with patients with DCIS.
KeywordsBreast cancer Microinvasive carcinoma Pathological features Molecular subtypes Prognosis
This work was supported by National Science Foundation of China (81470119; 81172532).
Conflicts of interest
- 8.Ellis IO, Tavassoli FA. Microinvasive carcinoma. In: Tavassoli FA, Devilee P, editors. Pathology & genetics: Tumours of the breast and female genital organs. 3rd ed. Lyon: IARC Press; 2003. p. 74–5.Google Scholar
- 10.Pinder SE, Ellis IO, Schnitt SJ, Tan PH, Rutgers E, Morrow M. Microinvasive carcinoma. In: Lakhani SR, Ellis IO, Schnitt SJ, editors. WHO classification of tumours of the breast. 4th ed. Lyon: IARC Press; 2012. p. 96–7.Google Scholar
- 12.Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B. Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206–23.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Olivotto I, Levine M. Clinical practice guidelines for the care and treatment of breast cancer: the management of ductal carcinoma in situ (summary of the 2001 update). C M A J. 2001;165:912–3.Google Scholar
- 19.von Minckwitz G, Darb-Esfahani S, Loibl S, Huober J, Tesch H, Solbach C, et al. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—Results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat. 2012;132:863–70.CrossRefGoogle Scholar